Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/29644
Tipo de documento
ArtigoDireito Autoral
Acesso restrito
Data de embargo
2028-08-30
Coleções
- INI - Artigos de Periódicos [3488]
Metadata
Mostrar registro completo
THE FUTURE ROLE OF CD4 CELL COUNT FOR MONITORING ANTIRETROVIRAL THERAPY
Autor(es)
Afiliação
World Health Organization. Department of HIV/AIDS. Geneva, Switzerland./ University of Cape Town. Centre for Infectious Disease Epidemiology and Research. Cape Town, South Africa.
University of Cape Town. Institute of Infectious Disease and Molecular Medicine. Clinical Infectious Diseases Research Initiative. Cape Town, South Africa.
Chelsea and Westminster Hospital. London, UK.
Médecins Sans Frontières. Southern Africa Medical Unit. Cape Town, South Africa.
Liverpool University. Department of Pharmacology and Therapeutics. UK.
Clinton Health Access Initiative. Boston, MA, USA.
University of Cape Town. Centre for Infectious Disease Epidemiology and Research. Cape Town, South Africa.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Geneva University Hospital. Infectious Disease Service. HIV/AIDS Unit. Geneva, Switzerland.
YRG Centre for AIDS Research and Education. Chennai, India.
Thai Red Cross AIDS Research Centre. Bangkok, Thailand.
Institut de Recherche pour le Développement (IRD). Montpellier, France.
World Health Organization. Department of HIV/AIDS. Geneva, Switzerland.
University of the Witwatersrand and National health Laboratory Services. Department of Molecular Medicine and Haematology. Johannesburg, South Africa.
NIH. Eunice Kennedy Shriver National Institute of Child Health and Human Development. Maternal and Pediatric Infectious Disease Branch. Bethesda, MD, Rockville, USA.
University of Cape Town. Institute of Infectious Disease and Molecular Medicine. Clinical Infectious Diseases Research Initiative. Cape Town, South Africa.
Chelsea and Westminster Hospital. London, UK.
Médecins Sans Frontières. Southern Africa Medical Unit. Cape Town, South Africa.
Liverpool University. Department of Pharmacology and Therapeutics. UK.
Clinton Health Access Initiative. Boston, MA, USA.
University of Cape Town. Centre for Infectious Disease Epidemiology and Research. Cape Town, South Africa.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Geneva University Hospital. Infectious Disease Service. HIV/AIDS Unit. Geneva, Switzerland.
YRG Centre for AIDS Research and Education. Chennai, India.
Thai Red Cross AIDS Research Centre. Bangkok, Thailand.
Institut de Recherche pour le Développement (IRD). Montpellier, France.
World Health Organization. Department of HIV/AIDS. Geneva, Switzerland.
University of the Witwatersrand and National health Laboratory Services. Department of Molecular Medicine and Haematology. Johannesburg, South Africa.
NIH. Eunice Kennedy Shriver National Institute of Child Health and Human Development. Maternal and Pediatric Infectious Disease Branch. Bethesda, MD, Rockville, USA.
Resumo em Inglês
For more than two decades, CD4 cell count measurements have been central to understanding HIV disease progression, making important clinical decisions, and monitoring the response to antiretroviral therapy (ART). In well resourced settings, the monitoring of patients on ART has been supported by routine virological monitoring. Viral load monitoring was recommended by WHO in 2013 guidelines as the preferred way to monitor people on ART, and efforts are underway to scale up access in resource-limited settings. Recent studies suggest that in situations where viral load is available and patients are virologically suppressed, long-term CD4 monitoring adds little value and stopping CD4 monitoring will have major cost savings. CD4 cell counts will continue to play an important part in initial decisions around ART initiation and clinical management, particularly for patients presenting late to care, and for treatment monitoring where viral load monitoring is restricted. However, in settings where both CD4 cell counts and viral load testing are routinely available, countries should consider reducing the frequency of CD4 cell counts or not doing routine CD4 monitoring for patients who are stable on ART.
Compartilhar